Literature DB >> 17064062

3-aminoquinazolinediones as a new class of antibacterial agents demonstrating excellent antibacterial activity against wild-type and multidrug resistant organisms.

Edmund L Ellsworth1, Tuan P Tran, H D Hollis Showalter, Joseph P Sanchez, Brian M Watson, Michael A Stier, John M Domagala, Stephen J Gracheck, E Themis Joannides, Martin A Shapiro, Steve A Dunham, Debra L Hanna, Michael D Huband, Jeffrey W Gage, Joel C Bronstein, Jia Yeu Liu, Dai Q Nguyen, Rajeshwar Singh.   

Abstract

The 3-aminoquinzolinediones represent a new series of antibacterial agents structurally related to the fluoroquinolones. They are inhibitors of bacterial gyrase and topoisomerase IV and demonstrate clinically useful antibacterial activity against fastidious Gram-negative and Gram-positive organisms, including multidrug- and fluoroquinolone-resistant organisms. These agents also demonstrate in vivo efficacy in murine systemic infection models.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17064062     DOI: 10.1021/jm060505l

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  16 in total

Review 1.  In front of and behind the replication fork: bacterial type IIA topoisomerases.

Authors:  Claudia Sissi; Manlio Palumbo
Journal:  Cell Mol Life Sci       Date:  2010-02-18       Impact factor: 9.261

2.  Probing the differential interactions of quinazolinedione PD 0305970 and quinolones with gyrase and topoisomerase IV.

Authors:  Xiao-Su Pan; Katherine A Gould; L Mark Fisher
Journal:  Antimicrob Agents Chemother       Date:  2009-06-29       Impact factor: 5.191

3.  Activity of quinolone CP-115,955 against bacterial and human type II topoisomerases is mediated by different interactions.

Authors:  Katie J Aldred; Heidi A Schwanz; Gangqin Li; Benjamin H Williamson; Sylvia A McPherson; Charles L Turnbough; Robert J Kerns; Neil Osheroff
Journal:  Biochemistry       Date:  2015-01-23       Impact factor: 3.162

4.  Rational design, synthesis and testing of novel tricyclic topoisomerase inhibitors for the treatment of bacterial infections part 2.

Authors:  R Kirk; A Ratcliffe; G Noonan; M Uosis-Martin; D Lyth; O Bardell-Cox; J Massam; P Schofield; A Lyons; D Clare; J Maclean; A Smith; V Savage; S Mohmed; C Charrier; A-M Salisbury; E Moyo; N Ooi; N Chalam-Judge; J Cheung; N R Stokes; S Best; M Craighead; R Armer; A Huxley
Journal:  RSC Med Chem       Date:  2020-09-18

5.  Synthesis and evaluation of 1-cyclopropyl-2-thioalkyl-8-methoxy fluoroquinolones.

Authors:  Kevin R Marks; Muhammad Malik; Arkady Mustaev; Hiroshi Hiasa; Karl Drlica; Robert J Kerns
Journal:  Bioorg Med Chem Lett       Date:  2011-06-06       Impact factor: 2.823

6.  Comparison of in vitro activities of fluoroquinolone-like 2,4- and 1,3-diones.

Authors:  Lisa M Oppegard; Kathryn R Streck; Jonathan D Rosen; Heidi A Schwanz; Karl Drlica; Robert J Kerns; Hiroshi Hiasa
Journal:  Antimicrob Agents Chemother       Date:  2010-04-19       Impact factor: 5.191

7.  Novel Bacterial Topoisomerase Inhibitors with Potent Broad-Spectrum Activity against Drug-Resistant Bacteria.

Authors:  Cédric Charrier; Anne-Marie Salisbury; Victoria J Savage; Thomas Duffy; Emmanuel Moyo; Nathan Chaffer-Malam; Nicola Ooi; Rebecca Newman; Jonathan Cheung; Richard Metzger; David McGarry; Mark Pichowicz; Ralph Sigerson; Ian R Cooper; Gary Nelson; Hayley S Butler; Mark Craighead; Andrew J Ratcliffe; Stuart A Best; Neil R Stokes
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

8.  In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups.

Authors:  Michael D Huband; Michael A Cohen; Margaret Zurack; Debra L Hanna; Laura A Skerlos; Mark C Sulavik; Glenn W Gibson; Jeffrey W Gage; Edmund Ellsworth; Michael A Stier; Stephen J Gracheck
Journal:  Antimicrob Agents Chemother       Date:  2007-01-29       Impact factor: 5.191

9.  Structural basis of gate-DNA breakage and resealing by type II topoisomerases.

Authors:  Ivan Laponogov; Xiao-Su Pan; Dennis A Veselkov; Katherine E McAuley; L Mark Fisher; Mark R Sanderson
Journal:  PLoS One       Date:  2010-06-28       Impact factor: 3.240

10.  Use of gyrase resistance mutants to guide selection of 8-methoxy-quinazoline-2,4-diones.

Authors:  Nadezhda German; Muhammad Malik; Jonathan D Rosen; Karl Drlica; Robert J Kerns
Journal:  Antimicrob Agents Chemother       Date:  2008-09-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.